Time sequence of blood activation by nanoporous alumina: Studies on platelets and complement system.
In the present work, the time sequence of blood activation by alumina membranes with different porosities (20 and 200 nm in diameter) was studied. The membranes were incubated with whole blood from 2 min to 4 h. Platelet adhesion and activation in addition to complement activation was monitored at different time points. Evaluation of platelet adhesion and activation was done by determining the change in platelet number and the levels of thrombospondin-1 (TSP-1) in the fluid phase. Scanning electron microscopy studies were done to further evaluate platelet adhesion and morphology. Immunocytochemical staining was used to evaluate the presence of CD41 and CD62P antigens on the material surface. Complement activation was monitored by measuring C3a and sC5b-9 in plasma samples by means of enzyme immunoassays. Both alumina membranes displayed similar complement activation time profiles, with levels of C3a and sC5b-9 increasing with incubation time. A statistically significant difference between the membranes was found after 60 min of incubation. Platelet activation characteristics and time profile were different between the two membranes. Platelet adhesion increased over time for the 20 nm surface, while the clusters of microparticles on the 200 nm surface did not appreciably change during the course of the experiment. The release of TSP-1 increased with time for both membranes; however, much later for the 200 nm alumina (240 min) as compared to the 20 nm membrane (60 min). The surface topography of the alumina most probably influence protein transition rate, which in turn affects material platelet activation kinetics.
Ferraz
Natalia
N
Department of Physical and Analytical Chemistry, BMC, Uppsala University, Sweden. natalia.ferraz@ytbioteknik.uu.se
Ott
Marjam Karlsson
MK
Hong
Jaan
J
D000537:Aluminum Oxide / Q000737:chemistry / Q000494:pharmacology*; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D003167:Complement Activation / Q000187:drug effects*; D015926:Complement C3a / Q000378:metabolism; D015938:Complement Membrane Attack Complex / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D007700:Kinetics; D008567:Membranes, Artificial; D018613:Microscopy, Confocal; D008855:Microscopy, Electron, Scanning; D058608:Nanopores; D019007:P-Selectin / Q000378:metabolism; D010316:Particle Size; D015539:Platelet Activation / Q000187:drug effects*; D010973:Platelet Adhesiveness / Q000187:drug effects*; D010976:Platelet Count; D040201:Platelet Membrane Glycoprotein IIb / Q000378:metabolism; D016062:Porosity; D019700:Thrombospondin 1 / Q000378:metabolism
D015938:Complement Membrane Attack Complex; D008567:Membranes, Artificial; D019007:P-Selectin; D040201:Platelet Membrane Glycoprotein IIb; C047610:SC5b-9 protein complex; D019700:Thrombospondin 1; D015926:Complement C3a; D000537:Aluminum Oxide